Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clathrin light chain B is a cytosolic protein that forms part of the clathrin triskelion, which assembles into a cage-like structure mediating vesicle formation for receptor-mediated endocytosis and intracellular trafficking. In mammals, clathrin consists of three heavy chains and three light chains (A and B types), with the light chains playing roles in regulating clathrin assembly/disassembly, cargo selectivity, and connecting the endocytic machinery to the actin cytoskeleton. CLTB is not a receptor, enzyme, or classical therapeutic target but serves as a key structural/regulatory component in clathrin-mediated endocytosis, a universal process critical for nutrient uptake, receptor recycling, and synaptic transmission. Dysfunction in CLTB or its pathways can contribute to altered endocytosis and has been linked to the ability of pathogens to hijack endocytic machinery for cell entry, but there are no approved therapeutic drugs that specifically target CLTB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clathrin light chain B (CLTB).